Bausch + Lomb Corporation Stock Toronto S.E.

Equities

BLCO

CA0717051076

Medical Equipment, Supplies & Distribution

Delayed Toronto S.E. 01:04:41 2024-04-25 pm EDT 5-day change 1st Jan Change
20.34 CAD -0.88% Intraday chart for Bausch + Lomb Corporation +3.46% -10.28%
Sales 2024 * 4.66B 6.37B Sales 2025 * 4.91B 6.71B Capitalization 5.24B 7.16B
Net income 2024 * -143M -195M Net income 2025 * 56M 76.54M EV / Sales 2024 * 1.96 x
Net Debt 2024 * 3.88B 5.3B Net Debt 2025 * 3.41B 4.67B EV / Sales 2025 * 1.76 x
P/E ratio 2024 *
-53.2 x
P/E ratio 2025 *
127 x
Employees 13,300
Yield 2024 *
-
Yield 2025 *
-
Free-Float 11.16%
More Fundamentals * Assessed data
Dynamic Chart
Bausch + Lomb Reports "Statistically Significant" Results From Study of Nutritional Supplement for Dry Eyes MT
Bausch + Lomb Brief: Announcing "Statistically Significant" Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes MT
Bausch + Lomb Corporation Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes CI
RBC Previews Bausch Health's Q1, Trims Target to US$11 MT
RBC Cuts Bausch + Lomb Target to US$18, Reiterates Outperform, as Previews Q1 MT
Bausch + Lomb Q1 Results Likely to be Impacted by Foreign Exchange Headwinds, RBC Says MT
RBC Cuts Price Target on Bausch + Lomb to $18 From $20, Keeps Outperform Rating MT
Bausch Health Gets 'Positive' Court Ruling on Xifaxan With Market Odds of Bausch + Lomb Distribution at 32%, RBC Says MT
RBC Notes "Positive" Appellate Court Ruling For Bausch Health, But Thinks Market Assigning ~32% BLCO Distribution Odds MT
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating MT
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Corporation Announces Board Changes CI
Barclays Raises Price Target on Bausch + Lomb to $18 From $17, Maintains Equalweight Rating MT
Deutsche Bank on Bausch + Lomb's Q4 MT
More news
1 day-0.88%
1 week+3.46%
Current month-13.15%
1 month-10.32%
3 months+3.35%
6 months-9.60%
Current year-10.28%
More quotes
1 week
19.69
Extreme 19.69
20.54
1 month
19.04
Extreme 19.04
23.59
Current year
18.41
Extreme 18.41
23.87
1 year
18.41
Extreme 18.41
28.96
3 years
15.95
Extreme 15.95
28.96
5 years
15.95
Extreme 15.95
28.96
10 years
15.95
Extreme 15.95
28.96
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-03-05
Director of Finance/CFO 51 21-12-31
Chief Tech/Sci/R&D Officer 57 22-01-30
Members of the board TitleAgeSince
Chief Executive Officer 56 23-03-05
Director/Board Member 83 -
Director/Board Member 68 -
More insiders
Date Price Change Volume
24-04-25 20.34 -0.88% 656
24-04-24 20.52 +1.03% 2,152
24-04-23 20.31 +1.10% 500
24-04-22 20.09 -0.20% 3,006
24-04-19 20.13 +2.39% 1,800

Delayed Quote Toronto S.E., April 25, 2024 at 01:04 pm EDT

More quotes
Bausch + Lomb Corporation is a Canada-based global eye health company. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
14.9 USD
Average target price
19.79 USD
Spread / Average Target
+32.80%
Consensus